期刊文献+

生物标志物在冠心病诊断中的临床应用 被引量:1

Clinical application of biomarkers in the diagnosis of coronary heart disease
下载PDF
导出
摘要 目的探讨联合检测低密度脂蛋白(LDL)、血清铁蛋白(SF)、C反应蛋白(CRP)对冠状动脉粥样硬化性心脏病(冠心病)的诊断价值。方法125例确诊为冠心病的患者作为冠心病组,100例非冠心病患者作为对照组。比较两组患者的SF、CRP、LDL水平,SF、CRP、LDL单项检测与三项联合检测冠心病的敏感性。结果冠心病组SF(275.30±80.31)μg/L、CRP(7.63±2.21)mg/L、LDL(3.79±0.82)mmol/L均高于对照组的(158.60±51.20)μg/L、(2.78±1.25)mg/L、(3.05±0.93)mmol/L,差异有统计学意义(P<0.05)。SF、CRP、LDL单项检测冠心病的敏感性分别为65%、77%、65%,低于三项联合检测的90%,差异有统计学意义(P<0.05)。结论血清LDL、SF、CRP联合检测有助于初筛冠心病。 Objective To discuss the value of combined detection of low density lipoprotein(LDL),serum ferritin(SF)and C-reactive protein(CRP)in the diagnosis of coronary heart disease.Methods LDL,SF and CRP were measured in 125 patients with coronary heart disease and 100 patients without coronary heart disease for statistical analysis.Results SF(275.3±80.31)μg/L,CRP(7.63±2.21)mg/L and LDL(3.79±0.82)mmol/L in coronary heart disease group was higher than(158.6±51.2)μg/L,(2.78±1.25)mg/L and(3.05±0.93)mmol/L in the control group,and their difference was statistically significant(P<0.05).The sensitivity of single detection of SF,CRP and LDL biomarkers in coronary heart disease group was 65%,77%and 65%,respectively,which was lower than 90%of the combined detection,the difference was statistically significant(P<0.05).Conclusion Combined detection of LDL,SF and CRP in serum is helpful for screening coronary heart disease.
作者 邓海云 薛金方 DENG Hai-yun;XUE Jinfang(Department of Clinical Laboratory,Xiangzhou District Second People’s Hospital,Zhuhai 519000,China)
出处 《中国实用医药》 2020年第5期22-23,共2页 China Practical Medicine
关键词 冠心病 血清铁蛋白 C反应蛋白 低密度脂蛋白 Coronary heart disease Serum ferritin C-reactive protein Low density lipoprotein
  • 相关文献

参考文献9

二级参考文献112

  • 1李国娟,文芳.2型糖尿病患者超敏CRP水平与IMT关系初探[J].实用糖尿病杂志,2006,2(1):35-37. 被引量:11
  • 2周朝霞,强华,马爱群,程华,周萍.冠心病患者外周血炎症相关指标及ox-LDL和ox-LDL抗体的检测及其临床意义[J].中南大学学报(医学版),2006,31(2):258-262. 被引量:5
  • 3申文祥,党瑜华,陈魁,黄琼.冠状动脉粥样硬化性心脏病患者血浆可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平检测[J].郑州大学学报(医学版),2007,42(3):546-548. 被引量:11
  • 4Dover GJ, Vaffe D. Therapy for beta-thalassemia-aparadigm for the treatment of genetic disorders. N Eeng1 J Med. 1994, 331:609.
  • 5Ofivieri NF, Nathan DG, MBC Miffn J H, et al. Survival in mediclfy treated patients with homozygous beta-thalassemia. N Eng1 J Med. 1994, 331:574.
  • 6Poluru LR, Sana ZR, Samia S, et al. High percentage of patients with myelodysplastic syndromes(MDS) show mitochondrial DNA (mt-DNA) mutations. Blood. 2000, 96(suppl):1551.
  • 7Bayraktar Y, Koseoglu T, Temizer A, et al. Relationship between the serum alanine aminotransferase level at the end of interferon and histologic changes in wild-type and precore mutant hepatitis B virus infections. J Viral Hepatol. 1996, 3(3):137.
  • 8Martin VR, Nogueras F, Gonzalez A, et al. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolison. Rev Espo Enferm Dig. 1997, 89(7):523.
  • 9Crandal N, Milonan, N. Galloe AM, et al. Distribution of liver haemosiderin iron in 187 patients with various types of hepatic desease. APMIS. 1996, 104:220.
  • 10Harrison H, Adams PC. Hemochromatosis common genes, uncommon illness. Can Fam Physician. 2002, 48(15):1326.

共引文献81

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部